Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mei-Juan Tu

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 25, 2017
Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer CellsPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
An Iterative Approach to Polish the Nanopore Sequencing Basecalling for Therapeutic RNA Quality ControlZiyuan Wang, Mei-Juan Tu, Ziyang Liu, et al.
Communications Biology|October 1, 2025
A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality controlZiyuan Wang, Mei-Juan Tu, Ziyang Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2015
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve ChemosensitivityMei-Mei Li, Balasubrahmanyam Addepalli, Mei-Juan Tu, et al.
Placenta|March 16, 2017
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signalingLissa N Francois, Ludwik Gorczyca, Jianyao Du, et al.
Cancer Letters|November 4, 2018
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse modelsMei-Juan Tu, Pui Yan Ho, Qian-Yu Zhang, et al.
Theranostics|March 23, 2021
<i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapyPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Frontiers in Oncology|March 13, 2020
The Optimal Outcome of Suppressing Ewing Sarcoma Growth <i>in vivo</i> With Biocompatible Bioengineered miR-34a-5p ProdrugDai-Feng Li, Ying Yuan, Mei-Juan Tu, et al.
Oncotarget|April 19, 2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsChao Jian, Mei-Juan Tu, Pui Yan Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2018
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer TherapyPui Yan Ho, Zhijian Duan, Neelu Batra, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 25, 2017
Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer CellsPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
An Iterative Approach to Polish the Nanopore Sequencing Basecalling for Therapeutic RNA Quality ControlZiyuan Wang, Mei-Juan Tu, Ziyang Liu, et al.
Communications Biology|October 1, 2025
A reference-guided iterative approach to polish the nanopore sequencing basecalling for therapeutic RNA quality controlZiyuan Wang, Mei-Juan Tu, Ziyang Liu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2015
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve ChemosensitivityMei-Mei Li, Balasubrahmanyam Addepalli, Mei-Juan Tu, et al.
Placenta|March 16, 2017
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signalingLissa N Francois, Ludwik Gorczyca, Jianyao Du, et al.
Cancer Letters|November 4, 2018
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse modelsMei-Juan Tu, Pui Yan Ho, Qian-Yu Zhang, et al.
Theranostics|March 23, 2021
<i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapyPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Frontiers in Oncology|March 13, 2020
The Optimal Outcome of Suppressing Ewing Sarcoma Growth <i>in vivo</i> With Biocompatible Bioengineered miR-34a-5p ProdrugDai-Feng Li, Ying Yuan, Mei-Juan Tu, et al.
Oncotarget|April 19, 2017
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse modelsChao Jian, Mei-Juan Tu, Pui Yan Ho, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2018
Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer TherapyPui Yan Ho, Zhijian Duan, Neelu Batra, et al.
Pageof 5